Patents Assigned to Mount Sinai School of Medicine of New York University
-
Patent number: 7498424Abstract: The present invention relates to the identification of host cell proteins that interact with viral proteins required for virus replication, and high throughput assays to identify compounds that interfere with the specific interaction between the viral and host cell protein. Interfering compounds that inhibit viral replication can be used therapeutically to treat viral infection. The invention is based, in part, on the Applicants' discovery of novel interactions between proteins of the influenza virus and a human host cell proteins. One of these host cell proteins, referred to herein as NPI-1, interacts with influenza virus protein NP, and may be an accessory protein required for replication of influenza virus. Another of these host cell proteins, referred to herein as NS1I-1, interacts with influenza virus protein NS1. Compounds that interfere with the binding of the host cell and viral proteins, and inhibit viral replication can be useful for treating viral infection in vivo.Type: GrantFiled: November 24, 2003Date of Patent: March 3, 2009Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Peter Palese, Robert O'Neill
-
Patent number: 7494808Abstract: The present invention relates, to novel methods and substrates for the propagation of viruses. The invention relates to IFN-deficient substrates and methods for propagating viruses in these unconventional substrates. In particular, the invention relates to methods of propagating viruses in immature embryonated eggs, preferably six- to nine-day-old chicken eggs. The methods of the invention are particularly attractive for growing viruses suitable for use in vaccine and pharmaceutical formulations.Type: GrantFiled: September 20, 2004Date of Patent: February 24, 2009Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Peter Palese, Adolfo García-Sastre, Robert O'Neil
-
Publication number: 20090035784Abstract: The present invention provides a novel gene, designated herein as “NPC1L1”, that is associated with lipid or glucose metabolism. The invention further provides the use of the NPC1L1 gene and its corresponding protein to diagnose a lipid condition in a cell or tissue and to screen for novel therapeutic compounds useful for treating lipid disorders and other NPC1L1-associated or mediated diseases or disorders. The invention further provides specific inhibitors of NPC1L1.Type: ApplicationFiled: August 1, 2005Publication date: February 5, 2009Applicant: Mount Sinai School of Medicine of New York UniversityInventors: Yiannis Ioannou, Joanna P. Davies
-
Publication number: 20090010962Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.Type: ApplicationFiled: June 1, 2005Publication date: January 8, 2009Applicants: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY, ST. JUDE CHILDREN'S RESEARCH HOSPITAL, THE UNITED STATED OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTUREInventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
-
Publication number: 20080305079Abstract: The present invention relates to novel myeloid suppressor cells (MSCs) and to methods of isolating these MSCs are also included. The MSCs of the present invention can be used to treat or prevent autoimmune diseases or alloimmune responses. The MSCs of the present invention may also be used to reduce a T cell response, induce T regulatory cells, and produce T cell tolerance.Type: ApplicationFiled: January 8, 2007Publication date: December 11, 2008Applicant: Mount Sinai School of Medicine of New York UniversityInventor: Shu-Hsia Chen
-
Patent number: 7446098Abstract: This application provides methods of improving gene therapy by combining gene therapy with active site-specific chaperones (ASSCs). The ASSC increases the stability and efficiency of the protein encoded by the recombinant gene that is administered.Type: GrantFiled: February 17, 2004Date of Patent: November 4, 2008Assignee: Mount Sinai School of Medicine of New York UniversityInventor: Jian-Qiang Fan
-
Patent number: 7442379Abstract: This invention relates to genetically engineered Newcastle disease viruses and viral vectors which express heterologous genes or mutated Newcastle disease viral genes or a combination of viral genes derived from different strains of Newcastle disease virus. The invention relates to the construction and use of recombinant negative strand NDV viral RNA templates which may be used with viral RNA-directed RNA polymerase to express heterologous gene products in appropriate host cells and/or to rescue the heterologous gene in virus particles. In a specific embodiment of the invention, the heterologous gene product is a peptide or protein derived from the genome of a human immunodeficiency virus. The RNA templates of the present invention may be prepared by transcription of appropriate DNA sequences using any DNA-directed RNA polymerase such as bacteriophage T7, T3, SP6 polymerase, or eukaryotic polymerase I.Type: GrantFiled: September 16, 2002Date of Patent: October 28, 2008Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Adolfo Garcia-Sastre, Peter Palese
-
Patent number: 7442527Abstract: The present invention relates, in general, to a screening method for identifying novel viral proteins with interferon antagonizing function using a transfection-based assay, and the use of such proteins in isolating various types of attenuated viruses for the development of vaccine and pharmaceutical formulations. The invention also relates to the use of viral interferon antagonists in screening assays to identify potential anti-viral agents. The invention further relates to protocols utilizing interferon antagonists, e.g., NS1, to enhance gene therapy or DNA vaccination based on their ability to increase gene expression.Type: GrantFiled: March 14, 2006Date of Patent: October 28, 2008Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Peter M. Palese, Adolfo Garcia-Sastre, Christopher Basler
-
Publication number: 20080261820Abstract: The present invention relates to a family of graph-theory based methods for the analysis of intracellular signaling networks created from biomedical literature using data-mining processes or acquired through high-content experiments. The methods of the present invention can be used to identify functional dynamic modules within biological networks that can be analyzed quantitatively for input/output relationships. In particular, the present invention relates to a computer-aided method for the in-silico analysis of signaling and other cellular interaction pathways to rank drug targets, identify biomarkers, predict side effects, and classify/diagnose patients.Type: ApplicationFiled: August 1, 2006Publication date: October 23, 2008Applicant: Mount Sinai School of Medicine of New York UniversityInventors: Ravi Iyengar, Avi Ma'ayan
-
Publication number: 20080226558Abstract: The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy.Type: ApplicationFiled: March 24, 2008Publication date: September 18, 2008Applicant: Mount Sinai School of Medicine of New York UniversityInventors: Gordon M. Keller, Valerie Kouskoff, Atsushi Kubo, Hans Joerg Fehling
-
Publication number: 20080227128Abstract: The present invention relates to a novel BRET system. The BRET system can be used to identify modified recognition sites within a protein insert and to identify the compounds involved in modulation of a given modification. The BRET system of the present invention can also be used in a screening method construct insert to identify candidates for drug development.Type: ApplicationFiled: September 30, 2005Publication date: September 18, 2008Applicant: Mount Sinai School of Medicine of New York UniversityInventor: Dan P. Felsenfeld
-
Publication number: 20080215873Abstract: A device for presenting content to a user is utilized in combination with a general purpose computer. The computer has a processor, a computer communications interface, a computer memory and an operating system. The operating system has one or more file management tools. The device has a housing, a device communications interface and a device memory. The device memory comprises a boot partition which includes boot software. The boot software is copied from the device into the computer memory and is executed from the computer memory by the processor. The device memory also comprises a secure partition inaccessible by the file management tools and having content stored thereon. The device memory also comprises content delivery software, which is copied to the computer memory, and when executed by the processor from the computer memory can access the content from the secure partition and present it to the user as sensory data.Type: ApplicationFiled: March 24, 2008Publication date: September 4, 2008Applicant: Mount Sinai School of Medicine of New York UniversityInventor: Frederick S. Bobrow
-
Publication number: 20080200419Abstract: An alternatively spliced form of transforming growth factor-beta2 (TGF-?2), herein denoted ?6-TGF-?2 is disclosed. ?6-TGF-?2 differs from TGF-?2 in the sequence of the three C-terminal exons. This novel protein is secreted, induced by cytotoxic stress in hematopoietic stem cells, and specifically blocks the enhancing effects of TGF-?2 on adult stem cells. ?6-TGF-?2 can be used to protect stem cells from cytotoxic stress, and to enhance maintenance of these cells in vitro during retroviral transduction. In addition, ?6-TGF-?2 can be used to slow aging and extend longevity.Type: ApplicationFiled: March 6, 2008Publication date: August 21, 2008Applicant: Mount Sinai School of Medicine of New York UniversityInventors: Hans-Willem Snoeck, Juhyun Choi
-
Publication number: 20080182266Abstract: The present invention relates to the discovery, identification and characterization of a transient receptor potential channel, referred to herein as TRP8, which is expressed in taste receptor cells and associated with the perception of bitter and sweet taste. The invention encompasses TRP8 nucleotides, host cell expression systems, TRP8 proteins, fusion proteins, polypeptides and peptides, antibodies to the TRP8 protein, transgenic animals that express a TRP8 transgene, and recombinant “knock-out” animals that do not express TRP8. The invention further relates to methods for identifying modulators of the TRP8-mediated taste response and the use of such modulators to either inhibit or promote the perception of bitterness or sweetness. The modulators of TRP8 activity may be used as flavor enhancers in foods, beverages and pharmaceuticals.Type: ApplicationFiled: March 7, 2008Publication date: July 31, 2008Applicant: Mount Sinai School of Medicine of New York UniversityInventors: Robert F. MARGOLSKEE, Liquan HUANG, Minqing RONG, Marianna MAX, Cristian A. PEREZ
-
Publication number: 20080161252Abstract: Methods and compositions are provided for treating proliferative disorders, wherein the composition comprises at least one compound according to Formula I: wherein R1 is selected from the group consisting of —OH, —NH2, —NH—CH2—CO2H, —NH—CH(CH3)—CO2H, and —NH—C(CH3)2—CO2H, or a pharmaceutically acceptable salt of such a compound; and an anthracycline, e.g. doxorubicin, or a pharmaceutically acceptable salt thereof, or a platin, e.g. oxaliplatin, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 10, 2006Publication date: July 3, 2008Applicants: TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITYInventors: E. Premkumar Reddy, James F. Holland
-
Publication number: 20080139475Abstract: The present invention relates to novel therapies for cancer and, in particular, to therapies that are particularly suited to tumor cells resistant to other types of therapies such as radiation, chemotherapy, or combinations of both approaches. The invention provides methods for identifying and implementing strategies to inhibit a transcription factor which, in combination with other factors, renders the cells resistant and inhibits apopotosis of the cells. The invention provides an inhibitory ATF2 N-terminal fragment, specifically a fragment corresponding to amino acid residues 50-100 of ATF2 (termed peptide II). The invention provides methods for inhibiting tumor cell growth with such peptides.Type: ApplicationFiled: November 26, 2007Publication date: June 12, 2008Applicant: Mount Sinai School of Medicine of New York UniversityInventor: Ze'ev Ronai
-
Patent number: 7384774Abstract: The present invention relates methods of generating infectious negative-strand virus in host cells by an entirely vector-based system without the aid of a helper virus. In particular, the present invention relates methods of generating infectious recombinant negative-strand RNA viruses intracellularly in the absence of helper virus from expression vectors comprising cDNAs encoding the viral proteins necessary to form ribonucleoprotein complexes (RNPs) and expression vectors comprising cDNA for genomic viral RNA(s) (vRNAs) or the corresponding cRNA(s). The present invention also relates to methods of generating infectious recombinant negative-strand RNA viruses which have mutations in viral genes and/or which express, package and/or present peptides or polypeptides encoded by heterologous nucleic acid sequences.Type: GrantFiled: August 28, 2003Date of Patent: June 10, 2008Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Peter Palese, Adolfo Garcia-Sastre, George G Brownlee, Ervin Fodor
-
Patent number: 7363510Abstract: A device for presenting content to a user is utilized in combination with a general purpose computer. The computer has a processor, a computer communications interface, a computer memory and an operating system. The operating system has one or more file management tools. The device has a housing, a device communications interface and a device memory. The device memory comprises a boot partition which includes boot software. The boot software is copied from the device into the computer memory and is executed from the computer memory by the processor. The device memory also comprises a secure partition inaccessible by the file management tools and having content stored thereon. The device memory also comprises content delivery software, which is copied to the computer memory, and when executed by the processor from the computer memory can access the content from the secure partition and present it to the user as sensory data.Type: GrantFiled: May 26, 2004Date of Patent: April 22, 2008Assignee: Mount Sinai School of Medicine of New York UniversityInventor: Frederick S. Bobrow
-
Patent number: 7361489Abstract: The present invention relates to assays and kits for carrying out said assays for the rapid, automated detection of infectious pathogenic agents and normal and abnormal genes. The present invention further relates to methods for general amplification of genomic DNA and total mRNAs and for analyzing differential mRNA expression using the amplification methods disclosed herein.Type: GrantFiled: November 21, 2003Date of Patent: April 22, 2008Assignee: Mount Sinai School of Medicine of New York UniversityInventors: David Y. Zhang, Wandi Zhang, Jizu Yi
-
Patent number: RE40594Abstract: The present invention relates to methods for identifying inhibitors of the bitter taste response, and by methods of using such inhibitors to either block the perception of bitterness and/or promote the perception of a sweet taste. The inhibitors of the invention may be used as flavor enhancers in foods and pharmaceuticals. The methods of the invention may further be used to characterize the gustatory perception of novel tastants.Type: GrantFiled: March 28, 2006Date of Patent: December 2, 2008Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Robert F. Margolskee, Ding Ming